410 Medical secures $12M in financing for next-gen medical device
Durham-based 410 Medical, a medical device company developing new technologies for emergency and critical care, has raised $12 million from investors, including two North Carolina venture capital firms.
The new funding will be used to scale the company’s commercial operations and support the launch of its LifeFlow next-generation infuser, a hand-held device for quickly and precisely infusing blood and intravenous fluids in critically ill patients.
The funding round follows a $14 million Series B financing completed in March 2025.
"The heightened interest in this round reflects the confidence investors and customers have in 410 Medical's mission and products," said Kyle Chenet, chief executive officer at 410 Medical. "With this funding, we're able to expand our commercial reach, bringing LifeFlow to more clinicians and investing in the next generation of our technology. We're grateful to Orlando Health Ventures for leading this round and excited to welcome Tampa General and an additional strategic partner to our syndicate."
Other investors included Durham-based Hatteras Venture Partners, Ballad Health, OSF Healthcare, Raleigh-based Rex Health Ventures, CU Healthcare Innovations Fund, Sarnova and Catalyst by Wellstar.
"Orlando Health Ventures is proud to lead this round and deepen our partnership with 410 Medical," said Bobby Helmedag, managing director of Orlando Health Ventures. "LifeFlow addresses a critical gap in resuscitative care, and we've seen firsthand the impact it can have for clinicians and patients. We're excited to support the team as they scale commercial operations and advance the next generation of the LifeFlow infuser."
LifeFlow products are used by more than 500 hospitals and emergency medical services (EMS) agencies across the country to help clinicians deliver fluid and blood quickly for patients experiencing sepsis, hemorrhagic shock and other life-threatening conditions. Nearly 80,000 patients have been treated using LifeFlow.
The company said the latest financing would enable it to accelerate LifeFlow adoption by more hospital systems and EMS agencies nationwide.
The next-generation device, planned for launch in 2027, builds on feedback from nearly 10 years of experience partnering with front-line medical providers working to provide effective resuscitation for critically ill patients. The new LifeFlow technology will address speed, portability, ease of use and other needs, according to the company.
Early funding from NCBiotech
410 Medical was founded by Raleigh physician Mark Piehl, M.D., and venture capitalist Luke Roush in 2013.
In 2016, the company was awarded a $250,000 Small Business Research Loan by the North Carolina Biotechnology Center. The loan program supports business inception and research critical to developing products, processes, or tools with clear commercial potential.
That same year, the Food and Drug Administration cleared LifeFlow for commercial use.
410 Medical lists 38 employees on its website, up from 21 three years ago.
The company’s name is derived from the numerical calculation of a fluid-delivery goal in treating pediatric septic shock.
Read more on 410 Medical:
410 Medical completes $14M Series B financing | North Carolina Biotechnology Center
410 Medical’s LifeFlow PLUS Enters US Market | North Carolina Biotechnology Center